Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ardelyx, Inc. (ARDX)
USD5.25
+0.09 (+1.65%)
US NASDAQ Healthcare Biotechnology
Address
400 Fifth Avenue 2451
Waltham, MA, US
Waltham, MA, US
CEO
Michael G. Raab
Website
ardelyx.com
IPO
2014-06-19
CIK 1437402 ISIN US0396971071
Description
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.25
+0.09 (+1.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.61
Float Shares
234.53M
Free Float %
95.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -6.64% | +6.96% | -5.71% | +9.44% | +13.38% | +87.25% | +54.08% | +293.45% | +308.02% | +87.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
5.25
Low
15.00
+186.0%
Consensus
17.00
+224.1%
Median
17.00
+224.1%
High
19.00
+262.2%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
17.50
+233.7%
|
| Last Year | 9 |
15.33
+192.3%
|
| All Time | 17 |
12.76
+143.3%
|
Quality scores
Altman Z-Score
1.27
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+22.1% ★ Q1'26: +27.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-52.9% Q1'26: +11.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-24.6% Q1'26: -34.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-10.1% Q1'26: -34.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-36.0% Q1'26: -110.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.5% ★ Q1'26: +3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.58× Q1'26: -1.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.03M
est: 23.41M (+2.6%)
|
2.61M
est: 2.50M (+4.3%)
|
5.28M
est: 3.75M (+40.7%)
|
7.57M
est: 6.92M (+9.4%)
|
10.10M
est: 9.75M (+3.6%)
|
52.16M
est: 34.15M (+52.7%)
|
124.46M
est: 210.00M (-40.7%)
|
333.62M
est: 327.38M (+1.9%)
|
407.32M
est: 400.15M (+1.8%)
|
545.48M
540.06M – 551.25M
+36.3% YoY
|
737.58M
695.81M – 772.96M
+35.2% YoY
|
978.58M
978.55M – 978.60M
+32.7% YoY
|
1.26B
1.20B – 1.31B
+28.5% YoY
|
1.41B
1.35B – 1.46B
+12.0% YoY
|
| EBITDA |
-28.56M
est: -16.36M (-74.6%)
|
-85.08M
est: -1.75M (-4,769.0%)
|
-84.57M
est: -2.62M (-3,124.4%)
|
-85.24M
est: -4.84M (-1,661.6%)
|
-150.85M
est: -130.80M (-15.3%)
|
-60.98M
est: -133.97M (+54.5%)
|
-55.35M
est: -108.69M (+49.1%)
|
-16.71M
est: -169.45M (+90.1%)
|
-37.92M
est: -207.11M (+81.7%)
|
-282.33M
-285.32M – -279.53M
-36.3% YoY
|
-381.76M
-400.08M – -360.15M
-35.2% YoY
|
-506.50M
-506.52M – -506.49M
-32.7% YoY
|
-650.99M
-676.38M – -623.58M
-28.5% YoY
|
-729.01M
-757.44M – -698.31M
-12.0% YoY
|
| EBIT |
-29.39M
est: -16.44M (-78.8%)
|
-87.76M
est: -1.76M (-4,898.5%)
|
-88.91M
est: -2.64M (-3,273.9%)
|
-89.21M
est: -4.86M (-1,735.0%)
|
-153.66M
est: -132.55M (-15.9%)
|
-62.13M
est: -135.54M (+54.2%)
|
-56.65M
est: -109.70M (+48.4%)
|
-18.78M
est: -171.03M (+89.0%)
|
-40.98M
est: -209.04M (+80.4%)
|
-284.96M
-287.98M – -282.13M
-36.3% YoY
|
-385.31M
-403.80M – -363.50M
-35.2% YoY
|
-511.21M
-511.23M – -511.20M
-32.7% YoY
|
-657.05M
-682.67M – -629.38M
-28.5% YoY
|
-735.79M
-764.49M – -704.81M
-12.0% YoY
|
| Net Income |
-29.62M
est: -341.09M (+91.3%)
|
-91.30M
est: -373.59M (+75.6%)
|
-94.94M
est: -350.21M (+72.9%)
|
-94.31M
est: -234.94M (+59.9%)
|
-158.17M
est: -135.94M (-16.4%)
|
-67.21M
est: -138.92M (+51.6%)
|
-66.07M
est: -65.14M (-1.4%)
|
-39.14M
est: -42.72M (+8.4%)
|
-61.60M
est: -58.06M (-6.1%)
|
-11.15M
-41.51M – 7.78M
+80.8% YoY
|
110.78M
64.12M – 150.29M
+1,093.4% YoY
|
268.75M
176.42M – 368.65M
+142.6% YoY
|
441.49M
417.33M – 463.88M
+64.3% YoY
|
537.02M
507.62M – 564.25M
+21.6% YoY
|
| SGA |
13.53M
est: 69.58M (-80.6%)
|
23.72M
est: 7.43M (+219.1%)
|
24.27M
est: 11.15M (+117.5%)
|
33.15M
est: 20.58M (+61.1%)
|
72.30M
est: 28.98M (+149.5%)
|
76.60M
est: 101.51M (-24.5%)
|
134.40M
est: 475.13M (-71.7%)
|
258.69M
est: 740.71M (-65.1%)
|
337.23M
est: 905.35M (-62.8%)
|
1.23B
1.22B – 1.25B
+36.3% YoY
|
1.67B
1.57B – 1.75B
+35.2% YoY
|
2.21B
2.21B – 2.21B
+32.7% YoY
|
2.85B
2.73B – 2.96B
+28.5% YoY
|
3.19B
3.05B – 3.31B
+12.0% YoY
|
| EPS |
-1.29
est: -1.45 (+11.0%)
|
-1.62
est: -1.59 (-2.0%)
|
-1.47
est: -1.49 (+1.3%)
|
-1.05
est: -1.00 (-5.1%)
|
-1.52
est: -1.51 (-0.4%)
|
-0.42
est: -0.51 (+17.4%)
|
-0.30
est: -0.28 (-6.3%)
|
-0.17
est: -0.17 (+1.3%)
|
-0.26
est: -0.24 (-7.2%)
|
-0.05
-0.17 – 0.03
+78.8% YoY
|
0.47
0.27 – 0.62
+1,004.3% YoY
|
1.14
0.73 – 1.53
+144.8% YoY
|
1.83
1.73 – 1.92
+60.7% YoY
|
2.23
2.11 – 2.34
+21.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-33.66M
OE per share TTM
-0.14
Owner's Yield
-2.07%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
53
Total invested
48.32M
Insider transactions (90d)
1
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 22.44M | 10.46% | — | — | — | 22.44M | HC | BOSTON MASSACHUSETTS | 2023-07-10 | ↗ |
| 2 | EIN #00-0000000 | 19.77M | 10.50% | — | 19.77M | — | 19.77M | IA, HC | Jersey, Channel Islands | 2023-01-10 | ↗ |
| 3 | SSGA FUNDS MANAGEMENT, INC. | 18.15M | 8.46% | — | — | — | 18.15M | IA | BOSTON MASSACHUSETTS | 2023-07-10 | ↗ |
| 4 | (1) BlackRock, Inc. | 16.78M | 7.20% | 16.40M | — | 16.78M | — | HC | Delaware | 2024-01-26 | ↗ |
| 5 | David Kroin | 14.25M | 8.45% | — | 14.25M | — | — | HC, IN | United States | 2022-09-12 | ↗ |
| 6 | Deep Track Biotechnology Master Fund, Ltd. | 14.25M | 8.45% | — | 14.25M | — | — | CO | Cayman Islands | 2022-09-12 | ↗ |
| 7 | Deep Track Capital, LP | 14.25M | 8.45% | — | 14.25M | — | — | IA, OO | Delaware | 2022-09-12 | ↗ |
| 8 | Forest Baskett | 13.66M | 15.30% | 22.9K | 13.63M | 22.9K | 13.63M | IN | — | 2020-06-18 | ↗ |
| 9 | NEA 15 GP, LLC | 13.63M | 15.30% | — | 13.63M | — | 13.63M | OO | — | 2020-06-18 | ↗ |
| 10 | The Vanguard Group - 23-1945930 | 13.03M | 5.61% | — | — | — | 520.6K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 11 | Israel A. Englander | 10.16M | 5.10% | — | 10.16M | — | 10.16M | IN | — | 2023-02-07 | ↗ |
| 12 | Millennium Group Management LLC | 10.16M | 5.10% | — | 10.16M | — | 10.16M | OO | — | 2023-02-07 | ↗ |
| 13 | Millennium Management LLC | 10.16M | 5.10% | — | 10.16M | — | 10.16M | OO | — | 2023-02-07 | ↗ |
| 14 | Patrick J. Kerins | 8.10M | 9.10% | 11.3K | 8.09M | 11.3K | 8.09M | IN | — | 2020-06-18 | ↗ |
| 15 | Mohamad H. Makhzoumi | 5.55M | 6.20% | 1.2K | 5.55M | 1.2K | 5.55M | IN | — | 2020-06-18 | ↗ |
| 16 | Joshua Makower | 5.55M | 6.20% | 340.00 | 5.55M | 340.00 | 5.55M | IN | — | 2020-06-18 | ↗ |
| 17 | Company, L.P. | 2.56M | 2.84% | — | 2.56M | — | — | PN | Delaware | 2021-02-12 | ↗ |
| 18 | Deerfield Mgmt, L.P. | 2.56M | 2.84% | — | 2.56M | — | — | PN | Delaware | 2021-02-12 | ↗ |
| 19 | Deerfield Partners, L.P. | 2.56M | 2.84% | — | 2.56M | — | — | PN | Delaware | 2021-02-12 | ↗ |
| 20 | James E. Flynn | 2.56M | 2.84% | — | 2.56M | — | — | IN | United States | 2021-02-12 | ↗ |
| 21 | Adage Capital Advisors, L.L.C. | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 22 | Adage Capital Partners GP, L.L.C. | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 23 | Adage Capital Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-10 | ↗ |
| 24 | Deerfield Special Situations Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2021-02-12 | ↗ |
| 25 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2021-11-15 | ↗ |
| 26 | Phillip Gross | — | 0.00% | — | — | — | — | IN | United States | 2022-02-10 | ↗ |
| 27 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | United States of America | 2021-11-15 | ↗ |
| 28 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | United States of America | 2021-11-15 | ↗ |
| 29 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2021-11-15 | ↗ |
| 30 | Robert Atchinson | — | 0.00% | — | — | — | — | IN | United States | 2022-02-10 | ↗ |
| 31 | Rock Springs Capital LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware | 2022-02-15 | ↗ |
| 32 | Rock Springs Capital Management LP | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 33 | Rock Springs Capital Master Fund LP | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2022-02-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
53
-183 vs prev Q
New positions
9
Closed positions
182
Increased
31
Reduced
12
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 9.33M +9.3M (+100.0%) | 54.39B +54.4B (+100.0%) | 3.86% +3.856 pp | 0.08% +0.082 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 21.14M +315.5K (+1.5%) | 123.24M +8.5M (+7.4%) | 8.74% +0.059 pp | 0.00% +0.000 pp | USD6.42 -9.2% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 18.98M +610.2K (+3.3%) | 110.65M +9.4M (+9.3%) | 7.85% +0.190 pp | 0.00% +0.000 pp | USD3.59 +62.4% | 46 qtrs — |
| 4 | JANUS HENDERSON GROUP PLC | 14.51M +690.6K (+5.0%) | 84.58M +8.4M (+11.1%) | 6.00% +0.238 pp | 0.04% +0.003 pp | USD3.80 +53.4% | 14 qtrs — |
| 5 | STATE STREET CORP | 11.91M +2.2M (+22.6%) | 69.45M +15.9M (+29.7%) | 4.92% +0.874 pp | 0.00% +0.001 pp | USD4.94 +18.0% | 46 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 11.91M +4.3M (+55.8%) | 69.43M +27.3M (+64.9%) | 4.92% +1.738 pp | 0.03% +0.011 pp | USD5.36 +8.8% | 26 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 5.83M +70.8K (+1.2%) | 33.98M +2.3M (+7.1%) | 2.41% +0.010 pp | 0.00% +0.000 pp | USD3.67 +58.9% | 46 qtrs — |
| 8 | MARSHALL WACE, LLP | 5.19M -3.8M (-42.0%) | 30.25M -19.0M (-38.6%) | 2.14% -1.583 pp | 0.03% -0.022 pp | USD4.66 +25.1% | 5 qtrs — |
| 9 | NUVEEN, LLC | 5.16M -10.4K (-0.2%) | 30.11M +1.6M (+5.6%) | 2.13% -0.022 pp | 0.01% +0.000 pp | USD5.09 +14.5% | 4 qtrs — |
| 10 | GOLDMAN SACHS GROUP INC | 3.06M +479.9K (+18.6%) | 17.87M +3.6M (+25.5%) | 1.27% +0.190 pp | 0.00% +0.000 pp | USD5.34 +9.2% | 40 qtrs — |
| 11 | TWO SIGMA INVESTMENTS, LP | 2.87M +383.1K (+15.4%) | 16.76M +3.0M (+22.1%) | 1.19% +0.150 pp | 0.02% +0.003 pp | USD5.33 +9.4% | 13 qtrs — |
| 12 | MORGAN STANLEY | 2.36M -526.5K (-18.2%) | 13.75M -2.1M (-13.5%) | 0.98% -0.228 pp | 0.00% 0.000 pp | USD4.64 +25.6% | 46 qtrs — |
| 13 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 2.30M +13.2K (+0.6%) | 13.41M +808.6K (+6.4%) | 0.95% -0.002 pp | 0.69% -0.049 pp | USD4.72 +23.5% | 5 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 2.21M -445.5K (-16.8%) | 12.88M -1.7M (-12.0%) | 0.91% -0.193 pp | 0.00% 0.000 pp | USD4.78 +22.0% | 45 qtrs — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.12M -77.5K (-3.5%) | 12.34M +250.7K (+2.1%) | 0.88% -0.040 pp | 0.00% +0.000 pp | USD4.21 +38.5% | 43 qtrs — |
| 16 | AQR CAPITAL MANAGEMENT LLC | 2.03M -119.0K (-5.6%) | 11.81M -7.9K (-0.1%) | 0.84% -0.057 pp | 0.01% -0.001 pp | USD5.05 +15.4% | 11 qtrs — |
| 17 | NORTHERN TRUST CORP | 2.02M -98.7K (-4.7%) | 11.77M +102.3K (+0.9%) | 0.83% -0.048 pp | 0.00% +0.000 pp | USD3.64 +60.2% | 45 qtrs — |
| 18 | ORACLE INVESTMENT MANAGEMENT INC | 1.87M +368.8K (+24.5%) | 10.92M +2.6M (+31.8%) | 0.77% +0.147 pp | 6.50% +1.324 pp | USD5.49 +6.2% | 13 qtrs — |
| 19 | JONES FINANCIAL COMPANIES LLLP | 1.85M -19.1K (-1.0%) | 10.81M +431.8K (+4.2%) | 0.77% -0.014 pp | 0.01% -0.001 pp | USD5.86 -0.5% | 7 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 1.79M +104.7K (+6.2%) | 10.46M +1.2M (+12.4%) | 0.74% +0.038 pp | 0.02% +0.004 pp | USD5.09 +14.5% | 4 qtrs — |
| 21 | EVERSEPT PARTNERS, LP | 1.72M +285.8K (+20.0%) | 10.00M +2.1M (+27.0%) | 0.71% +0.113 pp | 0.50% -0.039 pp | USD5.56 +4.9% | 2 qtrs — |
| 22 | J. GOLDMAN & CO LP | 1.62M +1.5M (+1,693.1%) | 9.46M +9.0M (+1,797.2%) | 0.67% +0.633 pp | 0.25% +0.237 pp | USD5.72 +1.9% | 3 qtrs — |
| 23 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.42M +845.9K (+146.1%) | 8.31M +5.1M (+160.4%) | 0.59% +0.348 pp | 0.00% +0.003 pp | USD5.70 +2.3% | 2 qtrs — |
| 24 | D. E. SHAW & CO., INC. | 1.41M -1.9M (-57.4%) | 8.23M -10.0M (-54.9%) | 0.58% -0.798 pp | 0.00% -0.006 pp | USD4.98 +17.1% | 7 qtrs — |
| 25 | TWO SIGMA ADVISERS, LP | 1.35M -265.9K (-16.5%) | 7.86M -1.0M (-11.6%) | 0.56% -0.115 pp | 0.02% -0.003 pp | USD5.00 +16.6% | 8 qtrs — |
| 26 | CITADEL ADVISORS LLC | 1.33M -201.1K (-13.2%) | 7.74M -683.2K (-8.1%) | 0.55% -0.088 pp | 0.00% 0.000 pp | USD6.24 -6.6% | 38 qtrs — |
| 27 | AIGH CAPITAL MANAGEMENT LLC | 1.15M +951.5K (+479.3%) | 6.70M +5.6M (+513.0%) | 0.48% +0.393 pp | 1.62% +1.315 pp | USD5.77 +1.0% | 2 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.10M +1.1M (+100.0%) | 6.39M +6.4M (+100.0%) | 0.45% +0.453 pp | 0.01% +0.007 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 29 | FIRST TRUST ADVISORS LP | 1.04M +853.9K (+467.6%) | 6.04M +5.0M (+500.6%) | 0.43% +0.352 pp | 0.00% +0.004 pp | USD5.49 +6.2% | 7 qtrs — |
| 30 | BNP PARIBAS ARBITRAGE, SNC | 1.00M +135.7K (+15.7%) | 5.84M +1.1M (+22.4%) | 0.41% +0.053 pp | 0.00% +0.000 pp | USD5.56 +4.9% | 44 qtrs — |
| 31 | HENNION & WALSH ASSET MANAGEMENT, INC. | 959.5K +179.2K (+23.0%) | 5.59M +1.3M (+30.1%) | 0.40% +0.071 pp | 0.19% +0.037 pp | USD5.90 -1.2% | 11 qtrs — |
| 32 | POINT72 ASSET MANAGEMENT, L.P. | 958.7K +958.7K (+100.0%) | 5.59M +5.6M (+100.0%) | 0.40% +0.396 pp | 0.01% +0.006 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 776.2K +156.2K (+25.2%) | 4.53M +1.1M (+32.5%) | 0.32% +0.063 pp | 0.00% +0.000 pp | USD5.06 +15.2% | 27 qtrs — |
| 34 | BARCLAYS PLC | 763.4K +216.0K (+39.5%) | 4.45M +679.3K (+18.0%) | 0.32% +0.087 pp | 0.00% +0.000 pp | USD4.80 +21.5% | 12 qtrs — |
| 35 | JANE STREET GROUP, LLC | 752.5K -144.4K (-16.1%) | 4.39M -554.8K (-11.2%) | 0.31% -0.063 pp | 0.00% 0.000 pp | USD5.98 -2.5% | 6 qtrs — |
| 36 | JPMORGAN CHASE & CO | 736.2K -267.1K (-26.6%) | 4.29M -1.2M (-22.4%) | 0.30% -0.114 pp | 0.00% 0.000 pp | USD5.30 +10.0% | 13 qtrs — |
| 37 | BANK OF NEW YORK MELLON CORP | 723.2K -16.2K (-2.2%) | 4.22M +142.0K (+3.5%) | 0.30% -0.009 pp | 0.00% +0.000 pp | USD3.09 +88.7% | 45 qtrs — |
| 38 | FREESTONE GROVE PARTNERS LP | 699.1K +297.4K (+74.0%) | 4.08M +1.9M (+84.1%) | 0.29% +0.122 pp | 0.03% +0.013 pp | USD5.31 +9.8% | 5 qtrs — |
| 39 | FMR LLC | 677.4K +656.0K (+3,066.9%) | 3.95M +3.8M (+3,250.9%) | 0.28% +0.271 pp | 0.00% +0.000 pp | USD5.81 +0.3% | 16 qtrs — |
| 40 | PANAGORA ASSET MANAGEMENT INC | 659.2K -527.0 (-0.1%) | 3.84M +208.0K (+5.7%) | 0.27% -0.003 pp | 0.01% -0.001 pp | USD6.21 -6.1% | 6 qtrs — |
| 41 | UBS GROUP AG | 578.3K +117.0K (+25.4%) | 3.37M +829.9K (+32.6%) | 0.24% +0.047 pp | 0.00% +0.000 pp | USD5.67 +2.8% | 45 qtrs — |
| 42 | DEUTSCHE BANK AG\ | 500.2K +306.2K (+157.8%) | 2.92M +1.8M (+172.8%) | 0.21% +0.126 pp | 0.00% +0.001 pp | USD5.11 +14.1% | 46 qtrs — |
| 43 | Y-INTERCEPT (HONG KONG) LTD | 499.7K +193.1K (+63.0%) | 2.91M +1.2M (+72.5%) | 0.21% +0.079 pp | 0.07% +0.025 pp | USD5.47 +6.6% | 3 qtrs — |
| 44 | SWISS NATIONAL BANK | 475.2K +11.3K (+2.4%) | 2.77M +214.3K (+8.4%) | 0.20% +0.003 pp | 0.00% +0.000 pp | USD4.73 +23.3% | 12 qtrs — |
| 45 | UBS ASSET MANAGEMENT AMERICAS INC | 431.2K +61.1K (+16.5%) | 2.51M +474.9K (+23.3%) | 0.18% +0.024 pp | 0.00% +0.000 pp | USD5.28 +10.4% | 12 qtrs — |
| 46 | RAFFERTY ASSET MANAGEMENT, LLC | 390.2K +75.4K (+24.0%) | 2.27M +540.5K (+31.2%) | 0.16% +0.030 pp | 0.01% +0.002 pp | USD4.99 +16.8% | 12 qtrs — |
| 47 | PRUDENTIAL FINANCIAL INC | 388.8K -60.4K (-13.4%) | 2.27M -208.2K (-8.4%) | 0.16% -0.027 pp | 0.00% 0.000 pp | USD4.90 +19.0% | 11 qtrs — |
| 48 | SCHRODER INVESTMENT MANAGEMENT GROUP | 368.4K +368.4K (+100.0%) | 2.14M +2.1M (+100.0%) | 0.15% +0.152 pp | 0.00% +0.002 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 49 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 347.6K +2.5K (+0.7%) | 2.03M +125.2K (+6.6%) | 0.14% 0.000 pp | 0.00% +0.000 pp | USD4.96 +17.5% | 4 qtrs — |
| 50 | SQUAREPOINT OPS LLC | 346.1K -50.7K (-12.8%) | 2.02M -168.5K (-7.7%) | 0.14% -0.022 pp | 0.00% +0.000 pp | USD4.79 +21.7% | 12 qtrs — |
| 51 | TREXQUANT INVESTMENT LP | 327.2K -177.2K (-35.1%) | 1.91M -871.5K (-31.4%) | 0.14% -0.075 pp | 0.02% -0.012 pp | USD5.27 +10.6% | 8 qtrs — |
| 52 | WELLS FARGO & COMPANY/MN | 318.4K +117.2K (+58.2%) | 1.86M +747.5K (+67.4%) | 0.13% +0.048 pp | 0.00% +0.000 pp | USD6.41 -9.0% | 45 qtrs — |
| 53 | INVESCO LTD. | 317.4K +59.6K (+23.1%) | 1.85M +430.0K (+30.3%) | 0.13% +0.024 pp | 0.00% +0.000 pp | USD5.02 +16.1% | 13 qtrs — |
| 54 | CLAY NORTHAM WEALTH MANAGEMENT, LLC | 315.0K -8.5K (-2.6%) | 1.84M +54.2K (+3.0%) | 0.13% -0.005 pp | 1.02% +0.002 pp | USD6.72 -13.2% | 9 qtrs — |
| 55 | PEKIN HARDY STRAUSS, INC. | 305.2K -97.0K (-24.1%) | 1.78M -436.8K (-19.7%) | 0.13% -0.042 pp | 0.16% -0.058 pp | USD1.09 +434.9% | 30 qtrs — |
| 56 | RHUMBLINE ADVISERS | 297.9K -43.0K (-12.6%) | 1.74M -141.4K (-7.5%) | 0.12% -0.019 pp | 0.00% 0.000 pp | USD3.80 +53.4% | 11 qtrs — |
| 57 | CAPITAL FUND MANAGEMENT S.A. | 283.9K -211.5K (-42.7%) | 1.66M -1.1M (-39.4%) | 0.12% -0.089 pp | 0.00% -0.003 pp | USD4.44 +31.3% | 6 qtrs — |
| 58 | RAIFFEISEN BANK INTERNATIONAL AG | 270.0K +270.0K (+100.0%) | 1.57M +1.6M (+100.0%) | 0.11% +0.112 pp | 0.02% +0.020 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 59 | LEGAL & GENERAL GROUP PLC | 268.3K -878.0 (-0.3%) | 1.56M +81.0K (+5.5%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD4.25 +37.2% | 12 qtrs — |
| 60 | ALLIANCEBERNSTEIN L.P. | 267.3K +— (+0.0%) | 1.56M +85.5K (+5.8%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD4.11 +41.8% | 11 qtrs — |
| 61 | DIADEMA PARTNERS LP | 252.2K -147.8K (-37.0%) | 1.47M -733.7K (-33.3%) | 0.10% -0.063 pp | 0.25% -0.311 pp | USD5.51 +5.8% | 2 qtrs — |
| 62 | IEQ CAPITAL, LLC | 246.4K -8.0K (-3.1%) | 1.44M +35.0K (+2.5%) | 0.10% -0.004 pp | 0.00% +0.000 pp | USD5.05 +15.4% | 4 qtrs — |
| 63 | PRICE T ROWE ASSOCIATES INC /MD/ | 234.5K +7.1K (+3.1%) | 1.37M +114.0K (+9.1%) | 0.10% +0.002 pp | 0.00% +0.000 pp | USD5.15 +13.2% | 13 qtrs — |
| 64 | WALLEYE CAPITAL LLC | 221.3K -989.8K (-81.7%) | 1.29M -5.4M (-80.7%) | 0.09% -0.413 pp | 0.00% -0.021 pp | USD5.50 +6.0% | 4 qtrs — |
| 65 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 217.7K +19.0 (+0.0%) | 1.27M +69.8K (+5.8%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD4.21 +38.5% | 12 qtrs — |
| 66 | JUMP FINANCIAL, LLC | 199.5K +161.9K (+430.5%) | 1.16M +955.7K (+461.3%) | 0.08% +0.067 pp | 0.01% +0.012 pp | USD5.77 +1.0% | 2 qtrs — |
| 67 | HEADLANDS TECHNOLOGIES LLC | 199.3K +108.1K (+118.6%) | 1.16M +659.5K (+131.3%) | 0.08% +0.044 pp | 0.10% +0.057 pp | USD5.68 +2.6% | 5 qtrs — |
| 68 | MACKENZIE FINANCIAL CORP | 199.6K +22.7K (+12.8%) | 1.16M +180.8K (+18.6%) | 0.08% +0.009 pp | 0.00% +0.000 pp | USD4.71 +23.8% | 11 qtrs — |
| 69 | STATE OF WISCONSIN INVESTMENT BOARD | 195.9K -49.2K (-20.1%) | 1.14M -208.4K (-15.4%) | 0.08% -0.021 pp | 0.00% -0.001 pp | USD4.32 +35.0% | 12 qtrs — |
| 70 | MONIMUS CAPITAL MANAGEMENT, LP | 194.7K -7.6K (-3.7%) | 1.14M +20.6K (+1.8%) | 0.08% -0.004 pp | 0.75% +0.062 pp | USD4.71 +23.8% | 4 qtrs — |
| 71 | RAYMOND JAMES FINANCIAL INC | 193.8K +103.8K (+115.3%) | 1.13M +633.9K (+127.8%) | 0.08% +0.043 pp | 0.00% +0.000 pp | USD5.45 +7.0% | 5 qtrs — |
| 72 | SG AMERICAS SECURITIES, LLC | 171.6K +39.7K (+30.1%) | 1.00M +273.0K (+37.6%) | 0.07% +0.016 pp | 0.00% -0.001 pp | USD5.56 +4.9% | 10 qtrs — |
| 73 | THRIVENT FINANCIAL FOR LUTHERANS | 162.8K +6.4K (+4.1%) | 949.0K +87.0K (+10.1%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD4.95 +17.8% | 4 qtrs — |
| 74 | LPL FINANCIAL LLC | 159.9K -2.1K (-1.3%) | 932.4K +39.4K (+4.4%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD5.11 +14.1% | 18 qtrs — |
| 75 | FRANKLIN RESOURCES INC | 154.7K -601.4K (-79.5%) | 901.9K -70.0M (-98.7%) | 0.06% -0.251 pp | 0.00% -0.017 pp | USD5.15 +13.2% | 16 qtrs — |
| 76 | HARBOR CAPITAL ADVISORS, INC. | 153.8K +53.7K (+53.7%) | 897.0K +345.0K (+62.5%) | 0.06% +0.022 pp | 0.07% +0.027 pp | USD4.95 +17.8% | 4 qtrs — |
| 77 | GROUP ONE TRADING, L.P. | 153.8K +60.5K (+64.9%) | 896.7K +382.8K (+74.5%) | 0.06% +0.025 pp | 0.00% +0.001 pp | USD6.85 -14.9% | 11 qtrs — |
| 78 | SIMPLEX TRADING, LLC | 151.9K -57.3K (-27.4%) | 885.8K -266.2K (-23.1%) | 0.06% -0.024 pp | 0.00% 0.000 pp | USD5.62 +3.7% | 25 qtrs — |
| 79 | PROFUND ADVISORS LLC | 145.3K +76.1K (+109.8%) | 847.3K +465.7K (+122.0%) | 0.06% +0.031 pp | 0.03% +0.013 pp | USD5.31 +9.8% | 12 qtrs — |
| 80 | PFG INVESTMENTS, LLC | 137.9K -435.0 (-0.3%) | 803.7K +41.7K (+5.5%) | 0.06% -0.001 pp | 0.04% -0.002 pp | USD4.77 +22.2% | 12 qtrs — |
| 81 | ENGINEERS GATE MANAGER LP | 137.6K -102.8K (-42.8%) | 802.1K -522.4K (-39.4%) | 0.06% -0.043 pp | 0.01% -0.006 pp | USD5.30 +10.0% | 5 qtrs — |
| 82 | ALGERT GLOBAL LLC | 134.2K +48.5K (+56.5%) | 782.0K +310.0K (+65.7%) | 0.06% +0.020 pp | 0.01% +0.004 pp | USD5.11 +14.1% | 7 qtrs — |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 134.0K +8.3K (+6.6%) | 780.7K +86.0K (+12.4%) | 0.06% +0.003 pp | 0.00% +0.000 pp | USD7.30 -20.1% | 7 qtrs — |
| 84 | CANADA PENSION PLAN INVESTMENT BOARD | 131.9K +131.9K (+100.0%) | 769.0K +769.0K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.001 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 85 | LION POINT CAPITAL, LP | 128.7K -34.1K (-21.0%) | 750.0K -146.7K (-16.4%) | 0.05% -0.015 pp | 3.88% -1.213 pp | USD2.55 +128.6% | 14 qtrs — |
| 86 | INTECH INVESTMENT MANAGEMENT LLC | 124.4K +11.1K (+9.8%) | 725.1K +100.8K (+16.1%) | 0.05% +0.004 pp | 0.01% +0.001 pp | USD5.58 +4.5% | 6 qtrs — |
| 87 | MAN GROUP PLC | 124.2K -70.7K (-36.3%) | 724.2K -349.9K (-32.6%) | 0.05% -0.030 pp | 0.00% -0.001 pp | USD4.45 +31.0% | 4 qtrs — |
| 88 | TUDOR INVESTMENT CORP ET AL | 123.4K -1.5K (-1.2%) | 719.5K +31.1K (+4.5%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD5.51 +5.8% | 5 qtrs — |
| 89 | XTX TOPCO LTD | 119.6K +119.6K (+100.0%) | 697.5K +697.5K (+100.0%) | 0.05% +0.050 pp | 0.02% +0.018 pp | USD5.83 +0.0% | 1 qtrs NEW |
| 90 | METLIFE INVESTMENT MANAGEMENT, LLC | 119.1K -18.2K (-13.3%) | 694.4K -62.2K (-8.2%) | 0.05% -0.008 pp | 0.00% 0.000 pp | USD5.51 +5.8% | 11 qtrs — |
| 91 | CAPTION MANAGEMENT, LLC | 115.0K +115.0K (+100.0%) | 670.5K +670.5K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.005 pp | USD5.83 +0.0% | 5 qtrs — |
| 92 | ACADIAN ASSET MANAGEMENT LLC | 113.3K +87.3K (+336.6%) | 656.0K +515.0K (+365.2%) | 0.05% +0.036 pp | 0.00% +0.001 pp | USD5.76 +1.2% | 2 qtrs — |
| 93 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 110.2K -6.5K (-5.5%) | 642.6K -412.0 (-0.1%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD5.30 +10.0% | 13 qtrs — |
| 94 | VIRTUS INVESTMENT ADVISERS, INC. | 110.0K -9.4K (-7.9%) | 641.6K -16.7K (-2.5%) | 0.05% -0.004 pp | 0.17% -0.014 pp | USD4.49 +29.8% | 4 qtrs — |
| 95 | WELLINGTON MANAGEMENT GROUP LLP | 100.1K -2.5K (-2.4%) | 583.5K +18.4K (+3.3%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD6.35 -8.2% | 9 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 91 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Biotechnology & Genome ETF PBE | 2.06% | 5.89M | 0.58% |
| 2 | Virtus Biotech ETF BBP | 1.20% | 1.18M | 0.34% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.36% | 130.7K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.36% | 39.27M | 0.35% |
| 5 | Inspire Small/Mid Cap ETF ISMD | 0.21% | 694.0K | 0.53% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.09% | 66.9K | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.09% | 999.9K | 0.35% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.09% | 415.2K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.09% | 67.0K | 0.19% |
| 10 | Vanguard Russell 2000 Growth ETF VTWG | 0.08% | 1.35M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.33
Bearish
Buys
1
Sells
2
Shares acquired
20.8K
Shares disposed
62.5K
Cash buys
—
Cash sales
1.00
Net activity
-41,668
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Ettenberg Felecia | Officer | — | — | Common Stock | 0 | 0.00 | — | 237,000 | D | ↗ |
| 2026-04-15 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 20,834 | 0.99 | 20.6K | 1,837,282 | D | ↗ |
| 2026-04-01 | Dinavahi Rajani | Officer | — | — | Common Stock | 0 | 0.00 | — | 201,000 | D | ↗ |
| 2026-03-16 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 20,833 | 0.99 | 20.6K | 1,856,986 | D | ↗ |
| 2026-02-24 | RAAB MICHAEL | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,833 | 0.99 | 20.6K | 395,001 | D | ↗ |
| 2026-02-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 7,192 | 5.87 | 42.2K | 437,066 | D | ↗ |
| 2026-02-20 | Reilly Joseph James | Officer | S-Sale | D | Common Stock | 4,387 | 5.87 | 25.7K | 152,394 | D | ↗ |
| 2026-02-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 2 | 5.70 | 11.40 | 1,856,986 | D | ↗ |
| 2026-02-20 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 333,333 | 5.84 | 1.95M | 3,302,918 | D | ↗ |
| 2026-02-20 | Kelliher Mike | Officer | S-Sale | D | Common Stock | 2 | 5.71 | 11.41 | 364,666 | D | ↗ |
| 2026-02-20 | Hohenleitner Susan | Officer | S-Sale | D | Common Stock | 247 | 5.71 | 1.4K | 230,533 | D | ↗ |
| 2026-02-20 | Foster Eric Duane | Officer | S-Sale | D | Common Stock | 1 | 5.70 | 5.70 | 425,970 | D | ↗ |
| 2026-02-20 | Brady James Parker | Officer | S-Sale | D | Common Stock | 309 | 5.71 | 1.8K | 262,912 | D | ↗ |
| 2026-02-20 | Bishop John E | Officer | S-Sale | D | Common Stock | 386 | 5.71 | 2.2K | 339,152 | D | ↗ |
| 2026-01-23 | Williams Laura A | Officer | A-Award | A | Stock Option (Right to Buy) | 124,040 | 7.77 | 963.8K | 124,040 | D | ↗ |
| 2026-01-23 | Reilly Joseph James | Officer | A-Award | A | Stock Option (Right to Buy) | 69,360 | 7.77 | 538.9K | 69,360 | D | ↗ |
| 2026-01-23 | RAAB MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 669,330 | 7.77 | 5.20M | 669,330 | D | ↗ |
| 2026-01-23 | Kelliher Mike | Officer | A-Award | A | Stock Option (Right to Buy) | 154,625 | 7.77 | 1.20M | 154,625 | D | ↗ |
| 2026-01-23 | Hohenleitner Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 128,505 | 7.77 | 998.5K | 128,505 | D | ↗ |
| 2026-01-23 | Foster Eric Duane | Officer | A-Award | A | Stock Option (Right to Buy) | 206,915 | 7.77 | 1.61M | 206,915 | D | ↗ |
| 2026-01-23 | Brady James Parker | Officer | A-Award | A | Common Stock | 99,455 | 0.00 | — | 265,455 | D | ↗ |
| 2026-01-23 | Bishop John E | Officer | A-Award | A | Stock Option (Right to Buy) | 186,500 | 7.77 | 1.45M | 186,500 | D | ↗ |
| 2026-01-08 | Williams Laura A | Officer | M-Exempt | A | Common Stock | 50,000 | 0.99 | 49.5K | 409,896 | D | ↗ |
| 2025-11-21 | Williams Laura A | Officer | S-Sale | D | Common Stock | 6,426 | 5.54 | 35.6K | 359,896 | D | ↗ |
| 2025-11-21 | Reilly Joseph James | Officer | S-Sale | D | Common Stock | 11,086 | 5.54 | 61.4K | 108,914 | D | ↗ |
| 2025-11-21 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 46,887 | 5.54 | 259.6K | 1,455,363 | D | ↗ |
| 2025-11-21 | Kelliher Mike | Officer | S-Sale | D | Common Stock | 5,560 | 5.54 | 30.8K | 271,181 | D | ↗ |
| 2025-11-21 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 5,995 | 5.54 | 33.2K | 299,895 | D | ↗ |
| 2025-11-21 | Foster Eric Duane | Officer | S-Sale | D | Common Stock | 5,814 | 5.54 | 32.2K | 295,684 | D | ↗ |
| 2025-11-04 | Hohenleitner Susan | Officer | — | — | Common Stock | 0 | 0.00 | — | 146,896 | D | ↗ |
| 2025-08-26 | Williams Laura A | Officer | S-Sale | D | Common Stock | 30,000 | 6.12 | 183.6K | 366,322 | D | ↗ |
| 2025-08-21 | Williams Laura A | Officer | S-Sale | D | Common Stock | 6,261 | 5.93 | 37.1K | 396,322 | D | ↗ |
| 2025-08-21 | Renz Justin A | Officer | S-Sale | D | Common Stock | 7,037 | 5.93 | 41.7K | 409,052 | D | ↗ |
| 2025-08-21 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 45,687 | 5.93 | 271.0K | 1,502,250 | D | ↗ |
| 2025-08-21 | Kelliher Mike | Officer | S-Sale | D | Common Stock | 5,417 | 5.93 | 32.1K | 276,741 | D | ↗ |
| 2025-08-21 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 5,841 | 5.93 | 34.6K | 305,890 | D | ↗ |
| 2025-08-21 | Foster Eric Duane | Officer | S-Sale | D | Common Stock | 15,308 | 5.93 | 90.8K | 301,498 | D | ↗ |
| 2025-08-01 | Conner Edward R. | Officer | — | — | Stock Option (Right to Buy) | 463,268 | 5.21 | 2.41M | 0 | D | ↗ |
| 2025-08-01 | Bishop John E | Officer | — | — | Stock Option (Right to Buy) | 327,000 | 4.49 | 1.47M | 0 | D | ↗ |
| 2025-06-18 | Rodgers Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 54,059 | 3.61 | 195.2K | 54,059 | D | ↗ |
| 2025-06-18 | Parsey Merdad | Director | A-Award | A | Common Stock | 15,235 | 0.00 | — | 57,291 | D | ↗ |
| 2025-06-18 | MOTT DAVID M | Director | A-Award | A | Common Stock | 31,163 | 0.00 | — | 2,928,034 | D | ↗ |
| 2025-06-18 | Cadoret-Manier Onaiza | Director | A-Award | A | Stock Option (Right to Buy) | 54,059 | 3.61 | 195.2K | 54,059 | D | ↗ |
| 2025-06-18 | Brady James Parker | Officer | — | — | Stock Option (Right to Buy) | 250,000 | 3.93 | 982.5K | 0 | D | ↗ |
| 2025-06-18 | Bhanji Muna | Director | A-Award | A | Stock Option (Right to Buy) | 54,059 | 3.61 | 195.2K | 54,059 | D | ↗ |
| 2025-06-18 | Bertrand William C JR | Director | A-Award | A | Stock Option (Right to Buy) | 54,059 | 3.61 | 195.2K | 54,059 | D | ↗ |
| 2025-06-18 | Bazemore Robert B | Director | A-Award | A | Common Stock | 41,551 | 0.00 | — | 41,551 | D | ↗ |
| 2025-06-16 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 200,000 | 3.63 | 725.9K | 2,896,871 | D | ↗ |
| 2025-06-09 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 200,000 | 3.69 | 737.3K | 2,696,871 | D | ↗ |
| 2025-05-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 6,421 | 4.08 | 26.2K | 402,583 | D | ↗ |
| 2025-05-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 7,218 | 4.08 | 29.5K | 416,089 | D | ↗ |
| 2025-05-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 46,817 | 4.08 | 191.1K | 1,547,937 | D | ↗ |
| 2025-05-20 | Kelliher Mike | Officer | S-Sale | D | Common Stock | 14,522 | 4.08 | 59.3K | 282,158 | D | ↗ |
| 2025-05-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 5,992 | 4.08 | 24.5K | 311,731 | D | ↗ |
| 2025-05-20 | Foster Eric Duane | Officer | S-Sale | D | Common Stock | 2,507 | 4.08 | 10.2K | 316,806 | D | ↗ |
| 2025-05-15 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 100,000 | 3.29 | 329.1K | 2,496,871 | D | ↗ |
| 2025-05-02 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 20,833 | 0.99 | 20.6K | 1,636,420 | D | ↗ |
| 2025-05-02 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 381,377 | 4.22 | 1.61M | 2,396,871 | D | ↗ |
| 2025-04-28 | Parsey Merdad | Director | A-Award | A | Stock Option (Right to Buy) | 64,457 | 5.35 | 344.8K | 64,457 | D | ↗ |
| 2025-04-04 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 20,833 | 0.99 | 20.6K | 1,657,253 | D | ↗ |
| 2025-03-07 | RAAB MICHAEL | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,834 | 0.99 | 20.6K | 457,500 | D | ↗ |
| 2025-02-25 | Williams Laura A | Officer | A-Award | A | Stock Option (Right to Buy) | 157,700 | 5.18 | 816.9K | 157,700 | D | ↗ |
| 2025-02-25 | Renz Justin A | Officer | A-Award | A | Stock Option (Right to Buy) | 205,019 | 5.18 | 1.06M | 205,019 | D | ↗ |
| 2025-02-25 | RAAB MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 855,326 | 5.18 | 4.43M | 855,326 | D | ↗ |
| 2025-02-25 | Kelliher Mike | Officer | A-Award | A | Stock Option (Right to Buy) | 205,019 | 5.18 | 1.06M | 205,019 | D | ↗ |
| 2025-02-25 | GRAMMER ELIZABETH A | Officer | A-Award | A | Stock Option (Right to Buy) | 205,019 | 5.18 | 1.06M | 205,019 | D | ↗ |
| 2025-02-25 | Foster Eric Duane | Officer | A-Award | A | Stock Option (Right to Buy) | 205,019 | 5.18 | 1.06M | 205,019 | D | ↗ |
| 2025-02-24 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 77,729 | 5.00 | 388.7K | 2,015,494 | D | ↗ |
| 2025-02-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 4,941 | 5.62 | 27.8K | 303,804 | D | ↗ |
| 2025-02-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 5,171 | 5.62 | 29.1K | 285,968 | D | ↗ |
| 2025-02-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 22,964 | 5.62 | 129.1K | 1,085,755 | D | ↗ |
| 2025-02-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 4,291 | 5.62 | 24.1K | 181,043 | D | ↗ |
| 2025-01-31 | RAAB MICHAEL | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,833 | 0.99 | 20.6K | 478,334 | D | ↗ |
| 2025-01-21 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 199,000 | 4.99 | 992.7K | 1,937,765 | D | ↗ |
| 2025-01-16 | Rodgers Richard J | Director | M-Exempt | A | Common Stock | 100,000 | 0.55 | 55.0K | 350,524 | D | ↗ |
| 2025-01-07 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 20,833 | 0.99 | 20.6K | 1,171,218 | D | ↗ |
| 2024-12-26 | MOTT DAVID M | Director | M-Exempt | A | Common Stock | 100,000 | 0.55 | 55.0K | 1,738,765 | D | ↗ |
| 2024-12-19 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 213,300 | 4.67 | 996.6K | 1,638,765 | D | ↗ |
| 2024-12-10 | RAAB MICHAEL | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 0.99 | 24.8K | 520,000 | D | ↗ |
| 2024-11-25 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 5.38 | 134.5K | 1,150,385 | D | ↗ |
| 2024-11-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 7,366 | 4.79 | 35.3K | 308,745 | D | ↗ |
| 2024-11-20 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 4,941 | 4.79 | 23.7K | 297,005 | D | ↗ |
| 2024-11-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 5,260 | 4.79 | 25.2K | 291,139 | D | ↗ |
| 2024-11-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 31,980 | 4.79 | 153.3K | 1,175,385 | D | ↗ |
| 2024-11-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 7,046 | 4.79 | 33.8K | 185,334 | D | ↗ |
| 2024-11-20 | Blanks Robert | Officer | S-Sale | D | Common Stock | 4,941 | 4.79 | 23.7K | 314,421 | D | ↗ |
| 2024-11-15 | Reilly Joseph James | Officer | — | — | Common Stock | 0 | 0.00 | — | 120,000 | D | ↗ |
| 2024-11-13 | MOTT DAVID M | Director | P-Purchase | A | Common Stock | 215,868 | 4.62 | 996.6K | 1,425,465 | D | ↗ |
| 2024-11-11 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 2,743 | 4.90 | 13.4K | 1,207,365 | D | ↗ |
| 2024-11-06 | Rosenbaum David P. | Officer | M-Exempt | A | Common Stock | 27,171 | 2.32 | 63.0K | 180,787 | I | ↗ |
| 2024-11-04 | Rosenbaum David P. | Officer | M-Exempt | A | Common Stock | 27,172 | 2.32 | 63.0K | 180,788 | I | ↗ |
| 2024-10-28 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.99 | 24.8K | 1,235,108 | D | ↗ |
| 2024-10-11 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 7,500 | 6.01 | 45.1K | 1,210,108 | D | ↗ |
| 2024-09-27 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 49,564 | 6.92 | 343.0K | 301,946 | D | ↗ |
| 2024-09-26 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 3,000 | 6.07 | 18.2K | 1,217,608 | D | ↗ |
| 2024-09-13 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 5,312 | 6.26 | 33.3K | 153,616 | — | ↗ |
| 2024-09-11 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 35,000 | 0.99 | 34.7K | 1,255,608 | — | ↗ |
| 2024-08-27 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 7,500 | 6.22 | 46.6K | 1,219,509 | — | ↗ |
| 2024-08-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 7,412 | 5.86 | 43.4K | 314,740 | — | ↗ |
| 2024-08-20 | Rosenbaum David P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,507 | 0.99 | 20.3K | 49,806 | — | ↗ |
| 2024-08-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 5,289 | 5.86 | 31.0K | 295,257 | — | ↗ |
| 2024-08-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 32,225 | 5.86 | 188.8K | 1,227,009 | — | ↗ |
| 2024-08-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 7,089 | 5.86 | 41.5K | 192,380 | — | ↗ |
| 2024-08-20 | Felsch Robert Ora | Officer | S-Sale | D | Common Stock | 3,567 | 5.86 | 20.9K | 91,560 | — | ↗ |
| 2024-08-20 | Blanks Robert | Officer | S-Sale | D | Common Stock | 4,969 | 5.86 | 29.1K | 319,362 | — | ↗ |
| 2024-08-16 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 20,000 | 5.94 | 118.7K | 356,479 | — | ↗ |
| 2024-08-12 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 1,229 | 5.71 | 7.0K | 1,259,234 | — | ↗ |
| 2024-08-08 | Foster Eric Duane | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 5.87 | 1.35M | 230,000 | — | ↗ |
| 2024-07-29 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 0.99 | 29.7K | 1,290,463 | — | ↗ |
| 2024-07-15 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 7,500 | 5.97 | 44.8K | 1,260,463 | — | ↗ |
| 2024-06-28 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 2,310 | 6.59 | 15.2K | 1,267,963 | — | ↗ |
| 2024-06-21 | Blanks Robert | Officer | S-Sale | D | Common Stock | 38,000 | 5.96 | 226.3K | 324,331 | — | ↗ |
| 2024-06-14 | Rodgers Richard J | Director | A-Award | A | Common Stock | 12,204 | 0.00 | — | 250,524 | — | ↗ |
| 2024-06-14 | MOTT DAVID M | Director | A-Award | A | Stock Option (Right to Buy) | 40,243 | 6.35 | 255.5K | 40,243 | — | ↗ |
| 2024-06-14 | Cadoret-Manier Onaiza | Director | A-Award | A | Stock Option (Right to Buy) | 40,243 | 6.35 | 255.5K | 40,243 | — | ↗ |
| 2024-06-14 | Bhanji Muna | Director | A-Award | A | Stock Option (Right to Buy) | 40,243 | 6.35 | 255.5K | 40,243 | — | ↗ |
| 2024-06-14 | Bertrand William C JR | Director | A-Award | A | Stock Option (Right to Buy) | 40,243 | 6.35 | 255.5K | 40,243 | — | ↗ |
| 2024-06-14 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 40,243 | 6.35 | 255.5K | 40,243 | — | ↗ |
| 2024-06-13 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 35,000 | 0.99 | 34.7K | 1,305,273 | — | ↗ |
| 2024-06-05 | Williams Laura A | Officer | M-Exempt | A | Common Stock | 100,000 | 2.75 | 275.0K | 467,152 | — | ↗ |
| 2024-06-03 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 17,872 | 7.00 | 125.1K | 158,502 | — | ↗ |
| 2024-05-29 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 7,500 | 6.72 | 50.4K | 1,270,273 | — | ↗ |
| 2024-05-21 | Williams Laura A | Officer | S-Sale | D | Common Stock | 4,794 | 7.81 | 37.4K | 367,152 | — | ↗ |
| 2024-05-21 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 4,855 | 7.81 | 37.9K | 376,479 | — | ↗ |
| 2024-05-21 | Rodriguez Susan | Officer | S-Sale | D | Common Stock | 6,703 | 7.81 | 52.4K | 449,092 | — | ↗ |
| 2024-05-21 | Renz Justin A | Officer | S-Sale | D | Common Stock | 5,167 | 7.81 | 40.4K | 300,546 | — | ↗ |
| 2024-05-21 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 31,484 | 7.81 | 245.9K | 1,277,773 | — | ↗ |
| 2024-05-21 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 6,927 | 7.81 | 54.1K | 199,469 | — | ↗ |
| 2024-05-21 | Felsch Robert Ora | Officer | S-Sale | D | Common Stock | 3,485 | 7.81 | 27.2K | 95,127 | — | ↗ |
| 2024-05-21 | Blanks Robert | Officer | S-Sale | D | Common Stock | 4,855 | 7.81 | 37.9K | 362,331 | — | ↗ |
| 2024-05-14 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 3,000 | 7.99 | 24.0K | 1,307,933 | — | ↗ |
| 2024-05-06 | GRAMMER ELIZABETH A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 109,687 | 2.75 | 301.6K | 241,313 | — | ↗ |
| 2024-05-06 | Felsch Robert Ora | Officer | M-Exempt | D | Stock Option (Right to Buy) | 79,101 | 0.84 | 66.4K | 61,525 | — | ↗ |
| 2024-05-03 | Williams Laura A | Officer | S-Sale | D | Common Stock | 39,949 | 8.35 | 333.6K | 370,189 | — | ↗ |
| 2024-05-03 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 45,000 | 9.00 | 405.0K | 267,993 | — | ↗ |
| 2024-04-29 | RAAB MICHAEL | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 0.99 | 29.7K | 1,340,933 | — | ↗ |
| 2024-04-15 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 7,500 | 7.06 | 52.9K | 1,310,933 | — | ↗ |
| 2024-04-01 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 1,518 | 7.31 | 11.1K | 1,318,433 | — | ↗ |
| 2024-03-25 | Kelliher Mike | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 86,000 | 7.73 | 665.0K | 312,993 | — | ↗ |
| 2024-03-15 | Blanks Robert | Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 367,186 | — | ↗ |
| 2024-02-26 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 5,183 | 9.20 | 47.7K | 175,936 | — | ↗ |
| 2024-02-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 4,803 | 8.75 | 42.0K | 380,138 | — | ↗ |
| 2024-02-20 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 2,294 | 8.75 | 20.1K | 181,119 | — | ↗ |
| 2024-02-20 | Rodriguez Susan | Officer | S-Sale | D | Common Stock | 6,928 | 8.75 | 60.6K | 452,795 | — | ↗ |
| 2024-02-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 5,341 | 8.75 | 46.7K | 304,835 | — | ↗ |
| 2024-02-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 22,917 | 8.75 | 200.4K | 1,319,951 | — | ↗ |
| 2024-02-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 4,432 | 8.75 | 38.8K | 398,993 | — | ↗ |
| 2024-02-20 | Felsch Robert Ora | Officer | S-Sale | D | Common Stock | 2,352 | 8.75 | 20.6K | 184,834 | — | ↗ |
| 2024-02-20 | Blanks Robert | Officer | S-Sale | D | Common Stock | 5,017 | 8.75 | 43.9K | 368,186 | — | ↗ |
| 2024-02-08 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 15,344 | 9.18 | 140.8K | 384,002 | — | ↗ |
| 2024-01-16 | Williams Laura A | Officer | A-Award | A | Stock Option (Right to Buy) | 152,127 | 8.78 | 1.34M | 152,127 | — | ↗ |
| 2024-01-16 | Rosenbaum David P. | Officer | A-Award | A | Stock Option (Right to Buy) | 99,000 | 8.78 | 869.2K | 99,000 | — | ↗ |
| 2024-01-16 | Rodriguez Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 145,000 | 8.78 | 1.27M | 145,000 | — | ↗ |
| 2024-01-16 | Renz Justin A | Officer | A-Award | A | Common Stock | 127,750 | 0.00 | — | 310,176 | — | ↗ |
| 2024-01-16 | RAAB MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 605,904 | 8.78 | 5.32M | 605,904 | — | ↗ |
| 2024-01-16 | GRAMMER ELIZABETH A | Officer | A-Award | A | Stock Option (Right to Buy) | 164,000 | 8.78 | 1.44M | 164,000 | — | ↗ |
| 2024-01-16 | Felsch Robert Ora | Officer | A-Award | A | Stock Option (Right to Buy) | 99,000 | 8.78 | 869.2K | 99,000 | — | ↗ |
| 2024-01-16 | Blanks Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 145,000 | 8.78 | 1.27M | 145,000 | — | ↗ |
| 2024-01-08 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 30,000 | 6.64 | 199.2K | 286,596 | — | ↗ |
| 2023-12-26 | Renz Justin A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 75,000 | 0.99 | 74.3K | 121,000 | — | ↗ |
| 2023-12-18 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 5,675 | 6.07 | 34.4K | 316,596 | — | ↗ |
| 2023-12-14 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 7,000 | 5.55 | 38.9K | 322,271 | — | ↗ |
| 2023-12-11 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 50,000 | 5.08 | 253.9K | 275,675 | — | ↗ |
| 2023-12-08 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 20,000 | 5.27 | 105.5K | 329,271 | — | ↗ |
| 2023-12-05 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 10,272 | 5.00 | 51.4K | 349,271 | — | ↗ |
| 2023-11-30 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 3,000 | 4.50 | 13.5K | 359,543 | — | ↗ |
| 2023-11-20 | Williams Laura A | Officer | S-Sale | D | Common Stock | 2,581 | 4.36 | 11.3K | 266,191 | — | ↗ |
| 2023-11-20 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 2,835 | 4.36 | 12.4K | 362,543 | — | ↗ |
| 2023-11-20 | Rodriguez Susan | Officer | S-Sale | D | Common Stock | 4,714 | 4.36 | 20.6K | 346,973 | — | ↗ |
| 2023-11-20 | Renz Justin A | Officer | S-Sale | D | Common Stock | 2,873 | 4.36 | 12.5K | 332,426 | — | ↗ |
| 2023-11-20 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 11,368 | 4.36 | 49.6K | 867,868 | — | ↗ |
| 2023-11-20 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 2,384 | 4.36 | 10.4K | 325,675 | — | ↗ |
| 2023-11-20 | Felsch Robert Ora | Officer | S-Sale | D | Common Stock | 1,044 | 4.36 | 4.6K | 117,066 | — | ↗ |
| 2023-11-20 | Blanks Robert | Officer | S-Sale | D | Common Stock | 2,835 | 4.36 | 12.4K | 260,453 | — | ↗ |
| 2023-11-15 | Williams Laura A | Officer | S-Sale | D | Common Stock | 25,000 | 4.00 | 100.0K | 266,839 | — | ↗ |
| 2023-10-10 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 1,644 | 4.00 | 6.6K | 365,378 | — | ↗ |
| 2023-09-08 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 2,897 | 4.55 | 13.2K | 367,022 | — | ↗ |
| 2023-08-21 | Williams Laura A | Officer | S-Sale | D | Common Stock | 2,591 | 3.55 | 9.2K | 291,839 | — | ↗ |
| 2023-08-21 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 937 | 3.55 | 3.3K | 111,225 | — | ↗ |
| 2023-08-21 | Rodriguez Susan | Officer | S-Sale | D | Common Stock | 4,733 | 3.55 | 16.8K | 348,687 | — | ↗ |
| 2023-08-21 | Renz Justin A | Officer | S-Sale | D | Common Stock | 2,884 | 3.55 | 10.2K | 333,849 | — | ↗ |
| 2023-08-21 | RAAB MICHAEL | Director / Officer | S-Sale | D | Common Stock | 11,419 | 3.55 | 40.6K | 876,236 | — | ↗ |
| 2023-08-21 | GRAMMER ELIZABETH A | Officer | S-Sale | D | Common Stock | 2,392 | 3.55 | 8.5K | 328,059 | — | ↗ |
| 2023-08-21 | Felsch Robert Ora | Officer | S-Sale | D | Common Stock | 1,048 | 3.55 | 3.7K | 115,110 | — | ↗ |
| 2023-08-21 | Blanks Robert | Officer | S-Sale | D | Common Stock | 2,846 | 3.55 | 10.1K | 263,288 | — | ↗ |
| 2023-06-27 | Williams Laura A | Officer | S-Sale | D | Common Stock | 25,000 | 3.35 | 83.6K | 294,430 | — | ↗ |
| 2023-06-23 | Blanks Robert | Officer | M-Exempt | A | Common Stock | 33,333 | 3.42 | 114.0K | 299,467 | — | ↗ |
| 2023-06-15 | Rodgers Richard J | Director | A-Award | A | Common Stock | 18,494 | 0.00 | — | 238,320 | — | ↗ |
| 2023-06-15 | MOTT DAVID M | Director | A-Award | A | Common Stock | 25,510 | 0.00 | — | 1,192,275 | — | ↗ |
| 2023-06-15 | Lundberg Jan M | Director | A-Award | A | Stock Option (Right to Buy) | 49,237 | 3.92 | 193.0K | 49,237 | — | ↗ |
| 2023-06-15 | Cadoret-Manier Onaiza | Director | A-Award | A | Stock Option (Right to Buy) | 49,237 | 3.92 | 193.0K | 49,237 | — | ↗ |
| 2023-06-15 | Block Geoffrey A. | Director | A-Award | A | Stock Option (Right to Buy) | 49,237 | 3.92 | 193.0K | 49,237 | — | ↗ |
| 2023-06-15 | Bhanji Muna | Director | A-Award | A | Stock Option (Right to Buy) | 49,237 | 3.92 | 193.0K | 49,237 | — | ↗ |
| 2023-06-15 | Bertrand William C JR | Director | A-Award | A | Common Stock | 16,581 | 0.00 | — | 218,743 | — | ↗ |
| 2023-06-15 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 49,237 | 3.92 | 193.0K | 49,237 | — | ↗ |
| 2023-05-23 | Williams Laura A | Officer | S-Sale | D | Common Stock | 2,583 | 3.65 | 9.4K | 319,430 | — | ↗ |
| 2023-05-23 | Rosenbaum David P. | Officer | S-Sale | D | Common Stock | 934 | 3.65 | 3.4K | 112,162 | — | ↗ |
| 2023-05-23 | Rodriguez Susan | Officer | S-Sale | D | Common Stock | 4,711 | 3.65 | 17.2K | 353,420 | — | ↗ |
| 2023-05-23 | Renz Justin A | Officer | S-Sale | D | Common Stock | 2,873 | 3.65 | 10.5K | 336,733 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-103.7K
Shares Outstanding
245.25M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Raab President, Chief Executive Officer and Director | 797.0K | — | 2.95M | 3.41M | 627.6K | 3.9K | 7.80M | 81.68% | ↗ |
| 2 | 2025 | Edward Conner, M.D. Former Chief Medical Officer | 213.0K | — | 1.57M | 1.84M | — | — | 3.62M | 94.12% | ↗ |
| 3 | 2025 | Justin Renz Former Chief Financial and Operations Officer | 464.4K | — | 1.58M | 1.18M | 250.4K | 75.5K | 3.55M | 77.75% | ↗ |
| 4 | 2025 | Susan Hohenleitner Chief Financial Officer | 120.9K | 330.0K | 735.9K | 2.19M | 56.4K | — | 3.44M | 85.24% | ↗ |
| 5 | 2025 | John Bishop, Ph.D. Chief Technical and Quality Officer | 240.0K | — | 1.00M | 1.15M | 116.5K | 3.0K | 2.51M | 85.69% | ↗ |
| 6 | 2025 | Elizabeth Grammer, Esq. Former Chief Legal and Administrative Officer | 527.1K | — | 708.0K | 818.3K | 246.7K | 3.5K | 2.30M | 66.26% | ↗ |
| 7 | 2024 | Michael Raab President, Chief Executive Officer and Director | 770.0K | — | 4.17M | 4.16M | 495.9K | 5.2K | 9.61M | 86.77% | ↗ |
| 8 | 2024 | Michael Kelliher EVP, Corporate Development and Strategy | 338.5K | — | 1.23M | 1.24M | 182.2K | — | 2.99M | 82.59% | ↗ |
| 9 | 2024 | Justin Renz Chief Financial and Operations Officer | 517.0K | — | 1.12M | 1.13M | 214.0K | 3.9K | 2.98M | 75.37% | ↗ |
| 10 | 2024 | Justin Renz Former Chief Financial and Operations Officer | 517.0K | — | 1.12M | 1.13M | 214.0K | 3.9K | 2.98M | 75.37% | ↗ |
| 11 | 2024 | Elizabeth Grammer Chief Legal and Administrative Officer | 509.3K | — | 1.12M | 1.13M | 210.9K | 4.3K | 2.97M | 75.64% | ↗ |
| 12 | 2024 | Elizabeth Grammer, Esq. Former Chief Legal and Administrative Officer | 509.3K | — | 1.12M | 1.13M | 210.9K | 4.3K | 2.97M | 75.64% | ↗ |
| 13 | 2024 | Laura Williams, M.D., M.P.H. Chief Medical Officer | 522.7K | — | 1.04M | 1.05M | 216.4K | — | 2.83M | 73.86% | ↗ |
| 14 | 2023 | Michael Raab President, Chief Executive Officer and Director | 700.0K | 330.0K | 687.5K | 2.40M | — | 5.0K | 4.12M | 74.87% | ↗ |
| 15 | 2023 | Elizabeth Grammer Chief Legal and Administrative Officer | 463.3K | 200.0K | 214.5K | 748.1K | — | 5.0K | 1.63M | 59.02% | ↗ |
| 16 | 2023 | Elizabeth Grammer, Esq. Former Chief Legal and Administrative Officer | 463.3K | 200.0K | 214.5K | 748.1K | — | 5.0K | 1.63M | 59.02% | ↗ |
| 17 | 2023 | Laura Williams, M.D., M.P.H. Chief Medical Officer | 483.6K | 181.2K | 214.5K | 748.1K | — | — | 1.63M | 59.15% | ↗ |
| 18 | 2022 | Michael Raab President, Chief Executive Officer and Director | 650.0K | 300.0K | 148.5K | 517.0K | 331.5K | — | 1.95M | 34.18% | ↗ |
| 19 | 2022 | Laura Williams, M.D., M.P.H. Chief Medical Officer | 465.0K | 250.0K | 39.6K | 141.8K | 158.8K | — | 1.06M | 17.19% | ↗ |
| 20 | 2022 | Susan Rodriguez Chief Commercial Officer | 455.8K | 150.0K | 139.6K | 144.0K | 155.0K | — | 1.04M | 27.16% | ↗ |
| 21 | 2021 | Michael Raab President, Chief Executive Officer and Director | 650.0K | 195.0K | 1.11M | 2.09M | 195.0K | — | 4.23M | 75.42% | ↗ |
| 22 | 2021 | Michael Raab, President, Chief Executive Officer and Director | 650.0K | 195.0K | 1.11M | 2.09M | 195.0K | — | 4.23M | 75.42% | ↗ |
| 23 | 2021 | Elizabeth Grammer, Esq. Chief Legal and Administrative Officer | 445.5K | 89.1K | 519.6K | 590.8K | 89.1K | — | 1.73M | 64.03% | ↗ |
| 24 | 2021 | Justin Renz Chief Financial Officer | 445.5K | 89.1K | 519.6K | 590.8K | 89.1K | — | 1.73M | 64.03% | ↗ |
| 25 | 2021 | Robert Blanks Chief Regulatory Affairs and Quality Assurance Officer | 422.0K | 84.4K | 519.6K | 590.8K | 84.4K | — | 1.70M | 65.27% | ↗ |
| 26 | 2021 | David Rosenbaum, Ph.D. Chief Development Officer | 461.0K | 92.2K | 394.6K | 590.8K | 92.2K | — | 1.63M | 60.42% | ↗ |
| 27 | 2020 | Michael Raab, President, Chief Executive Officer and Director | 633.3K | — | — | 3.01M | 314.3K | — | 3.95M | 76.03% | ↗ |
| 28 | 2020 | Michael Raab President & Chief Executive Officer | 633.3K | — | — | 3.01M | 314.3K | — | 3.95M | 76.03% | ↗ |
| 29 | 2020 | Susan Rodriguez Chief Commercial Officer | 273.6K | — | 154.0K | 1.25M | 145.2K | — | 1.82M | 77.02% | ↗ |
| 30 | 2020 | Justin Renz Chief Financial Officer | 242.8K | 10.0K | 73.5K | 1.00M | 141.9K | — | 1.47M | 73.11% | ↗ |
| 31 | 2019 | Michael Raab, President, Chief Executive Officer and Director | 595.0K | — | — | 740.9K | 393.0K | — | 1.73M | 42.85% | ↗ |
| 32 | 2019 | Michael Raab President & Chief Executive Officer | 595.0K | — | — | 740.9K | 393.0K | — | 1.73M | 42.85% | ↗ |
| 33 | 2019 | David Rosenbaum, Ph.D. Chief Development Officer | 428.3K | — | — | 195.4K | 189.0K | — | 812.7K | 24.05% | ↗ |
| 34 | 2019 | Elizabeth Grammer, Esq. Chief Legal and Administrative Officer | 414.0K | — | — | 195.4K | 182.0K | — | 791.4K | 24.69% | ↗ |
| 35 | 2018 | Michael Raab President & Chief Executive Officer | 575.0K | — | 860.0K | 2.54M | 205.6K | — | 4.18M | 81.34% | ↗ |
| 36 | 2018 | David Rosenbaum, Ph.D. Chief Development Officer | 414.0K | — | 430.0K | 760.2K | 107.6K | — | 1.71M | 69.53% | ↗ |
| 37 | 2018 | Elizabeth Grammer, Esq. Executive Vice President and General Counsel | 400.0K | — | 430.0K | 760.2K | 104.0K | — | 1.69M | 70.25% | ↗ |
| 38 | 2018 | Elizabeth Grammer, Esq. Chief Legal and Administrative Officer | 400.0K | — | 430.0K | 760.2K | 104.0K | — | 1.69M | 70.25% | ↗ |
| 39 | 2017 | Michael Raab President & Chief Executive Officer | 555.0K | — | 623.8K | 3.36M | 228.9K | — | 4.77M | 83.55% | ↗ |
| 40 | 2017 | Jeremy Caldwell, Ph.D. Chief Scientific Officer | 414.0K | — | 374.6K | 1.12M | 124.2K | — | 2.03M | 73.52% | ↗ |
| 41 | 2017 | David Rosenbaum, Ph.D. Chief Development Officer | 400.0K | — | 374.6K | 1.12M | 120.0K | — | 2.01M | 74.18% | ↗ |
| 42 | 2016 | Reginald Seeto, MBBS Chief Operating Officer | 82.3K | 250.0K | 1.50M | 1.49M | 43.0K | — | 3.37M | 88.86% | ↗ |
| 43 | 2016 | Paul Korner, M.D., M.B.A. Chief Medical Officer | 400.0K | 130.0K | 1,000.0K | 1.46M | 146.0K | — | 3.14M | 78.45% | ↗ |
| 44 | 2016 | Michael Raab President & Chief Executive Officer | 520.0K | — | — | 2.14M | 257.4K | — | 2.92M | 73.34% | ↗ |
| 45 | 2015 | Michael Raab President and Chief Executive Officer | 470.0K | — | — | 1.14M | 211.5K | — | 1.83M | 62.66% | ↗ |
| 46 | 2015 | Michael Raab President & Chief Executive Officer | 470.0K | — | — | 1.14M | 211.5K | — | 1.83M | 62.66% | ↗ |
| 47 | 2015 | Elizabeth Grammer, Esq. Senior Vice President General Counsel | 300.0K | — | — | 174.6K | 91.8K | 259.3K | 825.7K | 21.15% | ↗ |
| 48 | 2015 | Mark Kaufmann Chief Financial Officer | 320.0K | — | — | 361.4K | 117.8K | — | 799.2K | 45.22% | ↗ |
| 49 | 2014 | Jeremy Caldwell, Ph.D. | 32.1K | 100.0K | — | 2.20M | — | — | 2.33M | 94.33% | ↗ |
| 50 | 2014 | Dominique Charmot, Ph.D. Former Chief Scientific Officer | 311.1K | — | 835.9K | — | — | 512.0K | 1.66M | 50.38% | ↗ |
| 51 | 2014 | Michael Raab President and Chief Executive Officer | 426.7K | 39.3K | — | — | 130.7K | — | 596.7K | 0.00% | ↗ |
| 52 | 2014 | Michael Raab President and Chief Executive Officer | 426.7K | 39.3K | — | — | 130.7K | — | 596.7K | 0.00% | ↗ |
| 53 | 2014 | Mark Kaufmann Chief Financial Officer | 281.9K | 37.1K | — | — | 86.3K | — | 405.2K | 0.00% | ↗ |
| 54 | 2013 | Michael Raab President and Chief Executive Officer | — | — | — | — | 57.4K | — | 473.7K | 0.00% | ↗ |
| 55 | 2013 | Dominique Charmot, Ph.D. Former Chief Scientific Officer | 310.0K | — | — | — | 33.3K | — | 343.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael G. Raab | President, Chief Executive Officer & Director | 1M | male |
| Laura A. Williams | Chief Patient Officer & Interim Chief Medical Officer | 739.1K | — |
| Elizabeth A. Grammer | General Counsel | 724.4K | female |
| Rajani Dinavahi | Chief Medical Officer | 664.8K | female |
| Mike Kelliher | Chief Business Officer | 622.5K | male |
| Joseph Reilly | Senior Vice President of Finance & Principal Accounting Officer | — | male |
| Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | — | female |
| Sue Hohenleitner | Chief Financial Officer | — | female |
| Eric Duane Foster | Chief Commercial Officer | — | male |
| Felecia W. Ettenberg | Chief Legal Officer | — | female |
| James Brady | Chief Human Resources Officer | — | male |
| John Bishop | Chief Technical & Quality Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
